key: cord-1052823-5l2lt2ks authors: Segamarchi, Constanza; Silva, Berenice; Saidon, Patricia; Garcea, Orlando; Alonso, Ricardo title: Would it be recommended treating multiple sclerosis relapses with high dose oral instead intravenous steroids during the COVID-19 pandemic? Yes date: 2020-08-20 journal: Mult Scler Relat Disord DOI: 10.1016/j.msard.2020.102449 sha: 57ed3a15be93b9df01bcf046b6b67688e77fdf4f doc_id: 1052823 cord_uid: 5l2lt2ks The emergence of novel Coronavirus 2019 and the subsequent pandemic are presenting a challenge to neurologists managing patients with multiple sclerosis (MS). The clinical management has dramatically altered and it was necessary to change and/or adapt it to the new situation. Regarding relapses management, the use of intravenous corticosteroids and hospitalization during MS relapses increase the risk of viral exposure. Objective: To review the efficacy and safety of high dose oral corticosteroids in acute relapses treatment compared to intravenous corticosteroids. Methods: Descriptive review of the utility of high dose oral corticosteroids for MS relapses treatment was performed. We searched the literature available on PubMed and Scientific Electronic Library Online (Scielo). We focused on different trials comparing the use of high dose intravenous vs oral corticosteroids. Results: Five studies were selected. One hundred and eighty two patients receiving treatment with high dose oral corticosteroids were included. The most frequent schedule was oral methylprednisolone 1000 mg (over three days). There were no significant differences between both routes of corticosteroids administration. Conclusion: Neurologists should be aware of the current evidence on the similar efficacy of both oral and intravenous corticosteroids for MS relapses. Using oral steroids during the pandemic would be a safe option for patients. Would it be recommended treating multiple sclerosis relapses with high dose oral instead intravenous steroids during the COVID-19 pandemic? Yes. The emergence of novel Coronavirus 2019 and the subsequent pandemic are presenting a challenge to neurologists managing patients with multiple sclerosis (MS). The clinical management has dramatically altered and it was necessary to change and/or adapt it to the new situation. Regarding relapses management, the use of intravenous corticosteroids and hospitalization during MS relapses increase the risk of viral exposure. Objective: To review the efficacy and safety of high dose oral corticosteroids in acute relapses treatment compared to intravenous corticosteroids. Methods: Descriptive review of the utility of high dose oral corticosteroids for MS relapses treatment was performed. We searched the literature available on PubMed and Scientific Electronic Library Online (Scielo). We focused on different trials comparing the use of high dose intravenous vs oral corticosteroids. Results: Five studies were selected. One hundred and eighty two patients receiving treatment with high dose oral corticosteroids were included. The most frequent schedule was oral methylprednisolone 1000 mg (over three days). There were no significant differences between both routes of corticosteroids administration. Conclusion: Neurologists should be aware of the current evidence on the similar efficacy of both oral and intravenous corticosteroids for MS relapses. Using oral steroids during the pandemic would be a safe option for patients. were rapidly having to change and adapt in the face of the pandemic.5 Patients are seen virtually using telemedicine or phone calls and they were advised to take all preventive measures to reduce COVID-19 transmission (social-distancing, frequent hand-washing, respiratory hygiene) and also were recommended to avoid contact with the hospital and other medical institutions as much as possible. 6 Oral corticosteroids (oCS) may be preferable to intravenous corticosteroids in some patients with MS relapse.7 This administration route may relieve pressure on the hospitals that may be affected due to the pandemic and reduces the risk of COVID-19 transmission in these patients. In Argentina, there are no recommendations regarding relapses treatment during the COVID-19 pandemic. Therefore, patients are still hospitalized and receiving intravenous methylprednisolone (IVMP). The objective of this study is to make a descriptive review of the available literature about the efficacy of high doses oral corticosteroids for MS relapses treatment. In addition, we propose an algorithm of management and treatment during this pandemic context. We searched for the following terms in PubMed and Scientific Electronic Library online (Scielo): "Multiple Sclerosis", "MS", "relapse treatment", "oral corticosteroids", "high dose oral corticosteroids", "corticosteroids", "oral methylprednisolone", "oral prednisone", "intravenous corticosteroids", "IVMP", "oMP". Articles published from 1990 to March 2020 were selected. We identified 1021 potencial relevant records. Duplicate records, reviews, comments, nonrandomized trials or unrelated to topic were excluded. Studies were selected when they met the following entry criteria: randomized controlled trials, blinded or unblinded, comparing the use of high dose oCS and IVMP for MS relapses treatment. Five articles were selected and following variables were described: number of patients, dose and route administration of the treatment, outcomes, comparative efficacy and safety and/or tolerability. Table 1 summarizes the most important characteristics of each research. Out of five selected studies, three were double blind and four used high dose oral methylprednisolone (oMP).8-12 High dose oral prednisone (oP) as a treatment was applied in one trial. One hundred and eighty two patients receiving treatment with high dose oCS were included (160 oMP and 22 oP). The dose was from 500 mg to 1250 mg (three to five days). The most frequent oMP dose was 1000 mg (over three days). Three clinical trials provided initial evidence that high dose oMP can be administered to similar efficacy than IVMP in reducing EDSS and Gd-enhancing lesions after an MS relapse. 8, 9, 10 months and no significant difference between groups was found.12 Regarding side effects, there were no major adverse effects reported and no statistical differences were found between the groups, including gastrointestinal disorders. In COPOUSEP trial insomnia was more frequently reported in the oral group (77%) than intravenous group (64%). There were no significant differences between both oral and intravenous routes of corticosteroids administration. Neurologists should be aware of the current evidence on the efficacy of high doses oCS for MS relapses in order to apply into clinical practice. The goal in MS relapse treatment is to reduce the impact on patient quality of life. Any decision on relapse treatment during COVID-19 pandemic will need to be taken carefully considering patients' symptoms and ruling out an underlying infection. -Disability improvement: best-corrected visual acuity (BCVA) and scores on lowcontrast letters at 1 and 6 months. -MRI: not evaluated. -Others: recovery of the latency of the P100 component of the visual evoked potential at 6 months -Major adverse effects: no reported. -Minor adverse effects: 25 patients experienced at adverse effect. The most fr were: gastrointestinal (5 in group and 8 in the oral gro insomnia (4 in the IV group in the oral group); and tired or fatigue (5 in the IV group in the oral group). Clinical Characteristics of Coronavirus Disease 2019 in China Disease-Modifying Therapies During the COVID-19 Outbreak: A Narrative Review of the International and National Recommendations Multiple sclerosis and the risk of inf ection: considerations in the threat of the novel coronavirus, COVID-19/SARS-CoV-2 Multiple Sclerosis International Federation. The coronavirus and MS -global advice Treating multiple sclerosis and neuromyelitis optica spectrum disorder during the COVID-19 pandemic Management of multiple sclerosis relapses. CONTINUUM: Lifelong Learning in Neurology Oral versus intravenous steroids for treatment of relapses in multiple sclerosis Methylprednisolone in multiple sclerosis: a comparison of oral with intravenous therapy at equivalent high dose A single blind, randomised MRI study comparing high-dose oral and intravenous methylprednisolone in treating MS relapses A randomized clinical trial of oral versus intravenous methylprednisolone for relapse of MS Oral versus intravenous high-dose methylprednisolone for treatment of relapses in patients with multiple sclerosis (COPOUSEP): a randomised, controlled, double-blind, noninferiority trial Effect of treating acute optic neuritis with bioequivalent oral vs intravenous corticosteroids: a randomized clinical trial A meta-analysis of methylprednisolone in recovery from multiple sclerosis exacerbations Corticosteroids or ACTH for acute exacerbations in multiple sclerosis Treatment of acute relapses in multiple sclerosis at home with oral dexamethasone: a pilot study Oral versus intravenous corticosteroids in acute relapses of multiple sclerosis The bioavailability of IV methylprednisolone and oral prednisone in multiple sclerosis The bioavailability of IV methylprednisolone and oral prednisone in multiple sclerosis Multiple sclerosis relapses: epidemiology, outcomes and management. A systematic review Modifiable factors influencing relapses and disability in multiple sclerosis Relapse management in multiple sclerosis Treatment optimization in multiple sclerosis Telemedicine and Multiple Sclerosis: A Comprehensive Literature Review. Journal of telemedicine and telecare Telemedicine and remote care Validity and reproducibility of the Italian version of the patient determined disease steps scale in people with multiple sclerosis Validation of patient determined disease steps (PDDS) scale scores in persons with multiple sclerosis Use of Corticosteroids in Coronavirus Disease 2019 Pneumonia: A Systematic Review of the Literature RA has received personal compensation for consulting, serving on a scientific advisory board, lecturing as well as professional travel/accommodation stipends among other activities from Biogen Idec, Genzyme, Merck-Serono, Raffo, Novartis, Teva, Roche.BAS has received financial compensation for the development of educational, scientific activities and travels to conferences from Biogen, Novartis, Merck, Genzyme, TEVA, Bayer, Tuteur and Roche. The authors did not require a source of funding for this research